E-LIB Suche - Ergebnisse für: Schoedel, K.

1

P.031 Abuse potential assessment of the novel dual orexin r..:

Ufer, M. ; Kelsh, D. ; Schoedel, K..
European Neuropsychopharmacology. 40 (2020) - p. S21-S22 , 2020

Link: https://doi.org/10.1016/..

2

Assessment of human abuse potential of dasotraline compared..:

Koblan, K.S. ; Hopkins, S.C. ; Sarma, K....
Drug and Alcohol Dependence. 159 (2016) - p. 26-34 , 2016

Link: https://doi.org/10.1016/..

3

(442) Pharmacodynamic data assessing the abuse potential of..:

Setnik, B. ; Schoedel, K. ; Bartlett, C....
The Journal of Pain. 17 (2016) 4 - p. S85 , 2016

Link: https://doi.org/10.1016/..

4

(425) Evaluation of the relative intranasal abuse potential..:

Bond, M. ; Schoedel, K. ; Rabinovich-Guilatt, L....
The Journal of Pain. 16 (2015) 4 - p. S82 , 2015

Link: https://doi.org/10.1016/..

5

Update on tamper-resistant drug formulations:

Romach, M.K. ; Schoedel, K.A. ; Sellers, E.M.
Drug and Alcohol Dependence. 130 (2013) 1-3 - p. 13-23 , 2013

Link: https://doi.org/10.1016/..

6

Morphological and mechanical examination of the atrial 'int..:

Schwartzman, D. ; Schoedel, K. ; Stolz, D. B..
Europace. 15 (2013) 11 - p. 1557-1561 , 2013

Link: https://doi.org/10.1093/..

7

Opioid related adverse events in clinical trials- indicator..:

Levy-Cooperman, N. ; Schoedel, K.
The Journal of Pain. 14 (2013) 4 - p. S5 , 2013

Link: https://doi.org/10.1016/..

8

Evaluation of the Abuse Potential of Lorcaserin, a Serotoni..:

Shram, M J ; Schoedel, K A ; Bartlett, C...
Clinical Pharmacology & Therapeutics. 89 (2011) 5 - p. 683-692 , 2011

Link: https://doi.org/10.1038/..

9

P.6.c.010 Drug -induced changes in performance on the Divid..:

Harrison, S. ; Levy-Cooperman, N. ; Danilov, B..
European Neuropsychopharmacology. 21 (2011) - p. S581 , 2011

Link: https://doi.org/10.1016/..

10

Oral intact extended-release oxymorphone is associated with..:

Sellers, E. ; Schoedel, K. ; Mcmorn, S....
The Journal of Pain. 11 (2010) 4 - p. S21 , 2010

Link: https://doi.org/10.1016/..

11

P.6.c.010 Abuse potential of nabiximols oromucosal spray co..:

Schoedel, K.A. ; Chen, N. ; Guy, G.W....
European Neuropsychopharmacology. 20 (2010) - p. S587 , 2010

Link: https://doi.org/10.1016/..

12

Subjective and Objective Effects of the Novel Triple Reupta..:

Schoedel, K A ; Meier, D ; Chakraborty, B..
Clinical Pharmacology & Therapeutics. 88 (2010) 1 - p. 69-78 , 2010

Link: https://doi.org/10.1038/..

13

P.6.c.009 Eplivanserin has no significant abuse potential c..:

Schoedel, K.A. ; Saubadu, S. ; Delfolie, A...
European Neuropsychopharmacology. 20 (2010) - p. S586-S587 , 2010

Link: https://doi.org/10.1016/..

14

Oral intact extended-release oxymorphone is associated with..:

Sellers, E. ; Schoedel, K. ; Mcmorn, S....
The Journal of Pain. 11 (2010) 4 - p. S21 , 2010

Link: https://doi.org/10.1016/..

15

Recreational drug user preferences: Egalet® opioids have lo..:

Andersen, C. ; Hemmingsen, P.Høyrup ; Lindhardt, K...
The Journal of Pain. 10 (2009) 4 - p. S60 , 2009

Link: https://doi.org/10.1016/..